Milestone Pharmaceuticals

MIST

Market cap $162M

Overview Fund Trends Analyst Outlook Journalist POV

1.91 USD

+0.03

1.6%

At close Updated Oct 27, 4:00 PM EDT

Pre-market

After hours

1.93

+0.02

1.05%

1 day

1.6%

5 days

-4.5%

1 month

-5.91%

3 months

23.23%

6 months

41.48%

Year to date

-11.98%

1 year

31.72%

5 years

-66.37%

10 years

-87.57%

About: Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Employees: 33

Healthcare Biotechnology